Bloomberg News

Watson Rises as Generic Pain Patch Gets Regulatory Approval (1)

August 24, 2012

Watson Pharmaceuticals Inc. (WPI:US) rose after the drugmaker’s generic lidocaine patch to treat pain associated with shingles received U.S. regulatory approval.

Watson increased 6 percent to $83.32 at 4 p.m. New York time, its biggest gain in four months.

The patch is a copy of Endo Health Solutions Inc. (ENDP:US)’s numbing medication Lidoderm, Watson said in a statement yesterday. Watson plans to begin selling the product in September 2013. The Parsippany, New Jersey-based company said it’s eligible to sell the drug for six months without competition.

Watson and Chadds Ford, Pennsylvania-based Endo settled patent litigation (ENDP:US) related to lidocaine on May 29. Lidoderm is Endo’s best-selling drug, with the company reporting $825 million in sales (ENDP:US) last year.

Shingles is a painful, blistering skin rash caused by the virus that causes chicken pox, according to the National Institutes of Health.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net


Burger King's Young Buns
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • ENDP
    (Endo International PLC)
    • $68.53 USD
    • -0.81
    • -1.18%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus